Fanapt

Fanapt is a brand name of iloperidone, approved by the FDA in the following formulation(s):

FANAPT (iloperidone - tablet; oral)

• 
  Manufacturer: NOVARTIS
  
  Approval date: May 6, 2009
  
  Strength(s): 10MG, 12MG, 1MG ^[RLD], 2MG, 4MG, 6MG, 8MG
  

Has a generic version of Fanapt been approved?

No. There is currently no therapeutically equivalent version of Fanapt available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fanapt. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgesics
  Patent RE39198
  Issued: July 18, 2006
  Inventor(s): Strupczewski; Joseph T. & Helsley; Grover C. & Chiang; Yulin & Bordeau; Kenneth J. & Glamkowski; Edward J.
  Assignee(s): Aventis Pharmaceuticals Inc.
  Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amounts of one of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.
  
  Patent expiration dates:
  
  
  • November 15, 2016
    
    ✓ 
    Patent use: INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 6, 2014 - NEW CHEMICAL ENTITY
  
  

See also...

• Fanapt Consumer Information (Drugs.com)
• Fanapt Consumer Information (Wolters Kluwer)
• Fanapt Consumer Information (Cerner Multum)
• Fanapt Advanced Consumer Information (Micromedex)
• Fanapt Titration Pack Advanced Consumer Information (Micromedex)
• Fanapt AHFS DI Monographs (ASHP)
• Iloperidone Consumer Information (Wolters Kluwer)
• Iloperidone Consumer Information (Cerner Multum)
• Iloperidone Advanced Consumer Information (Micromedex)
• Iloperidone AHFS DI Monographs (ASHP)
• Iloperidonesee AHFS DI Monographs (ASHP)